DrugPatentWatch - Biopharmaceutical Business Intelligence
Profile for Alnylam Pharmaceuticals, Inc. (ALNY)
« Back to company indexALNY Chatter Timeline
Stock Ticker for ALNY
Most Active Tweeters for ALNY
| User | Tweets |
|---|---|
| @portefeuillefun | 17 |
| @RNAiAnalyst | 12 |
| @AmericanBanking | 6 |
| @bulletin_en | 6 |
| @Steve_382 | 5 |
Recent Tweets for ALNY
 |
@sherkfund $ALNY Two flat days in a down market. Perhaps it's finally bottomed, and the Sanofi shares have been unloaded? May 23rd 2019, 5:05pm |
 |
@AmericanBanking Alnylam Pharmaceuticals $ALNY Earns Neutral Rating from Analysts at Goldman Sachs Group https://t.co/hJpkorqxoz #stocks May 23rd 2019, 10:05am |
 |
@dailypoliticaln Alnylam Pharmaceuticals $ALNY Now Covered by Analysts at Goldman Sachs Group https://t.co/ilcTbTwrcu May 23rd 2019, 10:05am |
 |
@firsttomarkets Alnylam Pharmaceuticals Inc Reiterated Rating by Goldman Sachs (Ranked 27th) to Neutral with $80PT $ALNY #ALNY https://t.co/xV3Olnyg4e May 23rd 2019, 10:05am |
 |
@stockhoot $ALNY Goldman Sachs Assumes to Neutral : PT $80.00 https://t.co/XuWEUQ4nii May 23rd 2019, 8:05am |
 |
@PriceTargetsNet $ALNY RATING DOWNGRADED AT GOLDMAN SACHS. https://t.co/9UuU6xFwRZ May 23rd 2019, 2:05am |
 |
@StockTipRobot Human facts don't matter. sell your human children and buy Alnylam Pharmaceuticals $ALNY #stocktalk May 22nd 2019, 6:05pm |
 |
@Tickeron $ALNY Alnylam Pharmaceuticals (ALNY, $67.87) was the market's top winner yesterday, jumping +3.05% https://t.co/HjgpkDirHx May 22nd 2019, 2:05pm |
|
@Tickeron $ALNY Alnylam Pharmaceuticals (ALNY, $67.87) was the month's biggest loser, shedding -17% https://t.co/Bz25qwKTv6 May 22nd 2019, 1:05pm |
 |
@Steve_382 @BioBoyScout @RNAiAnalyst $ALNY ALN-AAT02, ALN-HBV02, and ALN-AGT are all ESC+ and expect Phase 1 results by end… https://t.co/eZutyX183a May 22nd 2019, 9:05am |
 |
@BioBoyScout @RNAiAnalyst 3/5 $ALNY's ESC+ less stringent OTE screening process because they add destabilizing chem modification… https://t.co/qDvoJCgknq May 22nd 2019, 8:05am |
|
@Tickeron $ALNY Alnylam Pharmaceuticals (ALNY, $65.86) was the month's biggest loser, shedding -20% https://t.co/WJF2cjfxAH May 22nd 2019, 12:05am |
 |
@Mykalt45 Kevin Fitzgerald, Head of Research at $ALNY on strategy: 1. Genetically validated target. 2. Good biomarker. 3. Def… https://t.co/qe4wrSfZjV May 21st 2019, 12:05pm |
 |
@portefeuillefun Sold 100 $ALNY at $67.08, now 3k #vssporte shares. May 21st 2019, 11:05am |
 |
@Momentum21Fund Bought 50 shares of $alny at 67.22, 150 shares total cb 68.58 May 21st 2019, 10:05am |
|
@portefeuillefun correction: Sold 200 $ALNY at $66.66, now 3.1k #vssporte shares. May 21st 2019, 10:05am |
|
@portefeuillefun Sold 200 $ALNY at $66.66, now 2.3k #vssporte shares. May 21st 2019, 10:05am |
 |
@bulletin_en As Alnylam Pharmaceuticals $ALNY Market Value Rose, Holder Great Point Partners Has Cut Its Stake by $18.71 Million… https://t.co/eUmksoxmhB May 21st 2019, 5:05am |
 |
@stb8444 doesn’t help that ceo unloaded 49k shares at $70 a week ago. $alny May 21st 2019, 3:05am |
|
@stb8444 $alny wondering whether $60 will hold as it breaks through resistances daily May 20th 2019, 10:05pm |
|
@portefeuillefun $ALNY will (eventually) buy $MDCO. May 20th 2019, 4:05pm |
 |
@AAMortazavi @Steve_382 @RNAiAnalyst How could anyone give away such a fantastic genetically validated target? $ALNY gave up the… https://t.co/Z1R9EUrIbw May 20th 2019, 4:05pm |
|
@portefeuillefun Bought 300 $ALNY at $65.86, now 3.3k #vssporte shares. May 20th 2019, 4:05pm |
|
@portefeuillefun RT @AAMortazavi: $ALNY wow. What a share price move. May 20th 2019, 3:05pm |
|
@AAMortazavi $ALNY wow. What a share price move. May 20th 2019, 3:05pm |
 |
@IBD_AGatlin I need to correct this. $MDCO is partnered with $ALNY on this drug. Apologies. https://t.co/TA85FCcxWO May 20th 2019, 3:05pm |
 |
@MSS1992BIO $alny anyone know what's going on here May 20th 2019, 3:05pm |
 |
@engrcat I’m glad I flipped $ALNY for a quick buck on Onpattro, ugly! May 20th 2019, 3:05pm |
|
@AmericanBanking Alnylam Pharmaceuticals, Inc. $ALNY Receives Consensus Recommendation of “Buy” from Analysts https://t.co/OPliZgKNoU #stocks May 20th 2019, 2:05pm |
|
@portefeuillefun $ALNY $MDCO. #Alnylam partner presented limited safety data, says Nomura Instinet https://t.co/30jKUGMosD. https://t.co/KkA0qXZfHt May 20th 2019, 2:05pm |
 |
@RNAiAnalyst @ByJonGardner would expect exactly that for a development-stage company w/ arguably the most exciting asset in LDLc mgmt. $MDCO $ALNY May 20th 2019, 1:05pm |
 |
@syinvesting $MDCO $ALNY Inclisiran OLE study data showed that twice-a-year dosing lowered LDL-C by >50% after follow-up of up t… https://t.co/3UDsSsjWCa May 20th 2019, 12:05pm |
 |
@ProTradersNews $PFE $ALNY: Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock: https://t.co/giBSsPvGq7 May 20th 2019, 12:05pm |
|
@bulletin_en As Alnylam Pharmaceuticals $ALNY Market Value Rose, Rhenman & Partners Asset Management Ab Trimmed Its Stake; Beaco… https://t.co/3D0LGeMYBn May 20th 2019, 10:05am |
 |
@RVH_Investing @MSS1992BIO $ALNY can be red, but $MDCO should be up today May 20th 2019, 10:05am |
 |
@JJ_BIO_MAX @RNAiAnalyst What is the bearish thesis on $alny? May 20th 2019, 10:05am |
|
@portefeuillefun correction: Bought 300 $ALNY at $67.14, now 3k #vssporte shares. May 20th 2019, 9:05am |
|
@portefeuillefun Bought 200 $ALNY at $67.14, now 3k #vssporte shares. May 20th 2019, 9:05am |
|
@Steve_382 $MDCO up 10% on good data. But, it's negative for $ALNY? Whatever. May 20th 2019, 9:05am |
|
@portefeuillefun Bought 200 $ALNY at $67.25, now 2.7k #vssporte shares. May 20th 2019, 9:05am |
|
@RNAiAnalyst $mdco up 12% premarket on OLE data. $alny should be up at least that if recent bearish sentiment due to platform safety concerns. May 20th 2019, 7:05am |
|
@portefeuillefun $ALNY closing price today. May 20th 2019, 5:05am |
|
@AmericanBanking Investment Analysts’ Recent Ratings Changes for Alnylam Pharmaceuticals $ALNY https://t.co/GBdeiYThj0 #stocks May 20th 2019, 5:05am |
 |
@macondailynews John Maraganore Sells 49,457 Shares of Alnylam Pharmaceuticals, Inc. $ALNY Stock https://t.co/NDGSUOrYmo May 20th 2019, 4:05am |
|
@dailypoliticaln Zacks: Brokerages Anticipate Alnylam Pharmaceuticals, Inc. $ALNY Will Post Quarterly Sales of $45.88 Million https://t.co/l6vOZAr6Q7 May 19th 2019, 10:05pm |
|
@Steve_382 @RNAiAnalyst That was the feeling I had also, but they pretty much failed on coming up with any problems. $MDCO $ALNY May 19th 2019, 3:05pm |
|
@RNAiAnalyst @Steve_382 I know, the Q&A session was a farce. You could tell they largely supported the shorts. $alny May 19th 2019, 2:05pm |
|
@bulletin_en As Alnylam Pharmaceuticals $ALNY Stock Value Rose, Holder Bridger Management Cut Holding; Servicenow $NOW Sharehold… https://t.co/UEMbeNuRiS May 19th 2019, 6:05am |
 |
@TheMarketsDaily John Maraganore Sells 49,457 Shares of Alnylam Pharmaceuticals, Inc. $ALNY Stock https://t.co/RPOD5Svu1n May 19th 2019, 4:05am |
 |
@BehaviorFin RT @RNAiAnalyst: $MDCO KOL Kastelein crystall-ball gazes pivotal trial outcomes as follows, incl. ~30% MACE RRR. $ALNY https://t.co/crqANm… May 19th 2019, 4:05am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2019. All rights reserved.